COL5A1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P20908 |
---|---|
Other Accession | NP_000084.3 |
Clone Names | 91019031 |
Gene ID | 1289 |
---|---|
Other Names | Collagen alpha-1(V) chain, COL5A1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | COL5A1 |
---|---|
Function | Type V collagen is a member of group I collagen (fibrillar forming collagen). It is a minor connective tissue component of nearly ubiquitous distribution. Type V collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin. |
Cellular Location | Secreted, extracellular space, extracellular matrix {ECO:0000255|PROSITE-ProRule:PRU00793} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
COL5A1 encodes an alpha chain for one of the lowabundance fibrillar collagens. Fibrillar collagen molecules aretrimers that can be composed of one or more types of alpha chains.Type V collagen is found in tissues containing type I collagen andappears to regulate the assembly of heterotypic fibers composed ofboth type I and type V collagen. COL5A1 product is closelyrelated to type XI collagen and it is possible that the collagenchains of types V and XI constitute a single collagen type withtissue-specific chain combinations. Mutations in this gene areassociated with Ehlers-Danlos syndrome, types I and II. [providedby RefSeq].
References
Vitart, V., et al. Hum. Mol. Genet. 19(21):4304-4311(2010)Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Posthumus, M., et al. Med Sci Sports Exerc (2010) In press :Borck, G., et al. Am. J. Med. Genet. A 152A (8), 2090-2093 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.